Creative Medical Technology Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a net loss attributable to the company of $5,587,129 for the nine months ended September 30, 2026.

Key Highlights

  • Nine-month net loss: Creative Medical Technology Holdings reported a net loss attributable to the company of $5,587,129 for the nine months ended September 30, 2026, compared to $4,107,334 for the same period in 2025.
  • Third-quarter net loss: The company reported a net loss attributable to CMTH of $2,670,076 for the three months ended September 30, 2026, versus $1,235,934 in the prior-year quarter.
  • No revenues: The company recorded $0 in revenues for both the three and nine months ended September 30, 2026, according to the filing.
  • Cash position: Cash stood at $6,845,741 as of September 30, 2026, down from $7,208,126 at December 31, 2025.
  • Shares outstanding: As of November 6, 2026, there were 7,597,557 shares of common stock outstanding, up from 3,696,668 at December 31, 2025.
  • R&D and SG&A expenses: Research and development expenses totaled $2,602,546 and selling, general and administrative expenses totaled $3,076,296 for the nine months ended September 30, 2026.
  • Stock-based expense: The company recorded $970,000 in stock-based expense for the nine months ended September 30, 2026, compared to $3,485 in the prior-year period.

Creative Medical Technology Holdings Reports Wider Losses and Zero Revenue for Nine Months Ended September 30, 2026

According to the filing, Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) generated no revenues for the nine months ended September 30, 2026, compared to $3,000 for the same period a year earlier. Total operating expenses for the nine-month period rose to $5,747,268 from $4,198,832 in the prior-year period, driven primarily by research and development costs of $2,602,546 and selling, general and administrative expenses of $3,076,296, the company disclosed. Amortization of patent costs contributed an additional $68,426 to operating expenses.

The company reported an operating loss of $5,747,268 for the nine months ended September 30, 2026, partially offset by interest income of $168,823, resulting in a net loss before income taxes of $5,578,445, according to the filing. For the three months ended September 30, 2026, the operating loss was $2,725,952, with interest income of $62,474, yielding a quarterly net loss before taxes of $2,663,478. The net loss per share on a basic and diluted basis was $(1.19) for the nine-month period and $(0.40) for the third quarter, based on weighted average shares outstanding of 4,699,163 and 6,661,627, respectively.

The filing disclosed that total assets were $7,278,806 as of September 30, 2026, against total liabilities of $293,226, leaving total stockholders' equity of $6,954,896. During the nine months ended September 30, 2026, the company raised $4,057,380 net from the sale of common stock and exercise of warrants, and recorded $970,000 in stock-based expense related to 1,000,000 shares issued. The accumulated deficit reached $76,174,050 as of September 30, 2026, up from $70,586,921 at December 31, 2025. Net cash used in operating activities was $4,459,905 for the nine-month period, the filing stated.

What Was Disclosed

Creative Medical Technology Holdings filed its quarterly report covering the period ended September 30, 2026, disclosing zero revenues, a nine-month net loss attributable to the company of $5,587,129, cash of $6,845,741, and total stockholders' equity of $6,954,896 as of the reporting date.